Approach
Allure Capital is a single-principal family office. The seven criteria below govern the active mandate — direct investments into Australian healthcare-software, medical-device and clinical-technology businesses. They are short, blunt, and they explain ninety-five percent of why most proposals don't go anywhere. The passive public-markets allocation runs independently, on a separate cadence.
Investment philosophy
The seven criteria below are the screen. The philosophy below is the why. Both have been stable for a decade. Both are written down here for the same reason: founders pitching us deserve to know exactly what they're walking into.
Own capital, own decisions.
Allure invests Nathan's own balance sheet. There is no fund, no LPs, no quarterly capital calls, no mandate document a committee has to vote to amend. Every active investment is one person's decision and one person's risk. That cuts both ways: deals close fast when they should, and they're killed fast when they shouldn't. There is no internal politics standing between a clean conviction and a wire transfer.
Operator capital, not financial capital.
The capital Allure deploys came from operating CommtechWireless from a Mosman Park shed in 1992 to a trade sale in 2008 — sixteen years of building a medical-communications platform across fifty-three countries. The active book is invested with that operator's perspective, not a financier's. We know what missing payroll feels like. We know what a deferred FDA submission costs. We know which board conversations actually move a business, and which are theatre.
Few deals, deep involvement.
One or two active investments a year. Each gets a board seat and roughly fifteen to twenty hours a month of Nathan's direct attention — not a junior associate's, not an investment committee's. The mandate is narrow because the work per deal is not. A typical engagement runs eighteen to thirty-six months and ends in an ASX listing, a trade sale, or a clean exit through a strategic acquirer. Generalist VC math doesn't work for us; concentrated medtech math does.
Patience on entry, discipline on exit.
We will sit on dry powder for twelve months without doing a deal if nothing fits. We won't extend the criteria to get a deal done. Equally, once the exit criteria are met, we move — we don't fall in love with positions. At Azure Healthcare (now Austco Healthcare), Allure divested its stake as the share price moved from 3.3¢ to 34¢ — roughly 10×. It ended deliberately, not by drift.
Two strategies, one balance sheet.
Active medtech investments and the passive public-markets allocation are sized so neither needs the other. The active book is funded from its own dry powder and its own realised exits; the passive book compounds on its own clock and is not raided to fund active deals. That separation is the whole point of running a family office across both — the active mandate gets to sit on its own clock, and the passive allocation gets to be boring.
Reputation compounds. So do mistakes.
We say no to about ninety-five percent of what we see, and we try to say it within a week — founders deserve to spend their time on conversations that might lead somewhere. We don't sign NDAs at first meeting; if the thesis can't survive a thirty-minute description, it isn't a thesis. We answer our own email. We don't blind-cc associates. The medtech investing world in Australia is small enough that how a firm behaves in the no's compounds at least as fast as how it performs in the yes's.
The seven criteria that operationalise this philosophy follow below. Every one of them has been in place since July 2016.
Seven criteria
01
The mandate is narrow on purpose. I invest where I have thirty-five years of operating context — medical communications, clinical decision support, hospital platforms, medical devices, diagnostics. We pass on everything else, including categories we like as consumers but don't understand as operators.
02
The technology works. The clinical pathway is established. The next thing the business needs is not another year of R&D — it's distribution, regulatory clearance for a new market, or the listing capital that converts traction into scale. We do not back pre-prototype or pre-clinical companies.
03
At least one institutional customer paying real money. Pilots with letters of intent do not count. Three paying customers is better than one; five is better than three. Revenue traction is the single best proxy for whether the team can sell into the healthcare buyer.
04
I invest with an exit in mind from day one. Either the business is on track for an ASX listing — reverse-takeover or direct — within three years, or it's building a strategic-acquirer profile that supports a trade sale on a similar timeline. Allure is not generalist VC and doesn't do ten-year holds.
05
Non-Executive Director, Executive Director, or Chair — the role depends on the company stage and my availability. Allure takes a governance role in every active position. Capital without governance is what made other people's portfolios go sideways, and we learnt from watching. This is a standard Allure holds itself to — not a price it asks of founders.
06
Allure invests its own capital. Below one hundred thousand is uneconomic for the work involved. Above one million sits outside the mandate of a single-principal vehicle — though we have the capacity to source larger amounts for syndication where the opportunity warrants it. Cheque size is a constraint, not a target.
07
The last criterion is the only one that isn't structural. Healthcare is a hard category and the path from clinical evidence to commercial scale almost always goes through at least one moment that the founder didn't expect. I invest in people I can stand alongside in those moments. The first meeting is usually enough to know.
The passive allocation
Active medtech is one strategy. The other is a long-term, low-cost public-markets allocation that runs on its own cadence — and isn't a source of capital that the active book draws against.
How it's run
The passive book is built from low-cost broad-market index funds and high-quality fixed-income instruments. It is rebalanced occasionally back toward target weights. No tactical trading, no manager-of-manager fees, no concentrated single-stock positions outside the active portfolio.
The point of running two strategies
The two strategies are sized so that an active investment never needs the passive book to be sold at a bad time to fund it. That separation is the whole point of running a family office across both — it lets the active mandate sit on its own clock, and it lets the passive allocation compound without being interrupted.
